by | Dec 23, 2024 | Lupus Foundation of America, News & Events
In a new study, the drug, deucravacitinib, proved to be a safe and more effective treatment for cutaneous lupus erythematosus disease (CLE, lupus skin disease) than two other commonly used therapies, anifrolumab and litifilimab. Lupus affects people differently, but...
by | Dec 19, 2024 | Lupus Foundation of America, News & Events
In a new study, researchers reviewed the advancements and ongoing challenges in the development of biologic therapies and disease prognosis of pediatric rheumatic diseases over the past 25 years, focusing on conditions including juvenile idiopathic arthritis (JIA),...
by | Dec 17, 2024 | Lupus Foundation of America
Jessica was thriving – she had moved into her first home, a cozy space that mirrored her vibrant personality and aspirations. Her career was flourishing, and she embraced her independence and personal growth confidently. But life threw an unexpected challenge...
by | Dec 13, 2024 | Lupus Foundation of America, News & Events
In a new study, researchers evaluated the treatment effects of BI655064, an anti-CD40 monoclonal antibody, as an add-on therapy for people living with lupus nephritis (LN, lupus related kidney disease). BI655064 is a humanized, antagonistic monoclonal antibody...
by | Dec 12, 2024 | Lupus Foundation of America, News & Events
Fate Therapeutics has announced encouraging initial data from the FT819 phase 1 autoimmunity study for people with moderate-to-severe systemic lupus erythematosus (SLE). The ongoing trial is evaluating safety, pharmacokinetics, and efficacy of FT819 in targeting CD19+...
by | Dec 6, 2024 | Lupus Foundation of America, News & Events
In a new study published in Lupus Science & Medicine, researchers found a connection between renal (kidney) response and long-term renal outcomes. People with lupus nephritis (LN, lupus-related kidney disease) who achieved modified primary efficacy renal response...
